Skip to main content

Table 3 Comparison of patients' symptoms at the time of admission and during hospitalization in the Modified ITT population

From: The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial

Symptoms—no. (%)

Group

P-value

Steroid + Azithromycin

Azithromycin

Lopinavir/Ritonavir

Total

Respiratory distress

17 (17.9)

13 (13.5)

6 (6.0)

36 (12.4)

0.041

Chill

33 (34.7)

36 (37.5)

35 (35.0)

104 (35.7)

0.910

Cough

65 (68.4)

70 (72.9)

78 (78.0)

213 (73.2)

0.341

Dyspnea

63 (66.3)

66 (68.8)

66 (66.0)

195 (67.0)

0.866

Chest pain

23 (24.2)

30 (31.3)

29 (29.0)

82 (28.2)

0.671

Anorexia

59 (62.1)

62 (64.6)

61 (61.0)

182 (62.5)

0.817

Diarrhea

17 (17.9)

21 (21.9)

21 (21.0)

59 (20.3)

0.779

Vomiting

9 (9.5)

17 (17.7)

13 (13.0)

39 (13.4)

0.261

Abdominal pain

15 (15.8)

15 (15.6)

16 (16.0)

46 (15.8)

0.991

Sore throat

12 (12.6)

13 (13.5)

14 (14.0)

39 (13.4)

0.853

Myalgia

45 (47.4)

48 (50.0)

56 (56.0)

149 (51.2)

0.499

Arthralgia

8 (8.4)

21 (21.9)

12 (12.0)

41 (14.1)

0.025

Fatigue

54 (56.8)

54 (56.3)

62 (62.0)

170 (58.4)

0.671

Headache

32 (33.7)

32 (33.3)

38 (38.0)

102 (35.1)

0.745